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Abstract
The treatment of cancer presents a clinical challenge both in human and veterinary medicine. Chemotherapy protocols
require the use of toxic drugs that are not always specific, do not selectively target cancerous cells thus resulting in
many side effects. A recent therapeutic approach takes advantage of the altered acidity of the tumour microenvironment
by using proton pump inhibitors (PPIs) to block the hydrogen transport out of the cell. The alteration of the extracellular
pH kills tumour cells, reverses drug resistance, and reduces cancer metastasis. Human clinical trials have prompted to
consider this as a viable and safe option for the treatment of cancer in companion animals. Preliminary animal studies
suggest that the same positive outcome could be achievable. The purpose of this review is to support investigations into
the use of PPIs for cancer treatment cancer in companion animals by considering the evidence available in both human
and veterinary medicine.
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Background
In recent years the role of pH in cancer has received in-
creasing attention from researchers worldwide. It is be-
coming clear that pH plays an important role in the
survival mechanisms of mammalian cancer cells and that
it is implicated in the resistance to drugs that some cancer
types develop during chemotherapy [1]. Over the last
40 years the number of human cancer deaths and new
cases per year has generally remained static, but the
survival times have been increasing gradually mainly due
to improved screening methods, and earlier detection
rather than advancements in treatment [2]. Currently, the
main reason for treatment failure is the development of
drug resistance [3], thus forcing scientists and clinicians to
rethink the way cancer is treated. Historically, clinicians
have used chemotherapy protocols to eradicate the growth
of fast proliferating tumour cells. However, the dose levels
required to overcome the developing resistance cause
human patients discomfort which can reach unacceptable
levels in the more advance stages of the disease, ultimately
resulting in the treatment failing to keep the cancer under
control. It is well known that cancer is not only a genetic
disease, but a condition which results from clonal selec-
tion of metabolic changes conferring cancer cells a growth
advantage [4]. In this context, it has been demonstrated
that extracellular pH plays an important role in drug re-
sistance and malignant progression [1]. Targeting tumour
pH can be therefore considered a valid and novel thera-
peutic strategy [5].
pH in cancer
Conventional therapies aimed at targeting proliferating
cancer cells often do not take in account cancer complexity
and tumour heterogeneity. In recent years, scientists have
studied cancer at the molecular level and investigated the
phenotypic changes and markers in different types of can-
cer [6]. One of the most important phenotypic changes is
the cancer cell’s ability to change the extracellular acidity
due to an altered glycolysis pathway [7]. Nearly a century
ago, Otto Warburg recognised the acidification of the
tumour microenvironment [8], postulating that cancer
cells use the less efficient anaerobic glycolysis pathway
even in the presence of oxygen, now known as the War-
burg hypothesis. This alternative pathway results in an
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intracellular accumulation of lactic acid which would lead
to cellular death if not removed. As such, the cancer cells
develop survival mechanisms to cope with this decreased
intracellular pH which allow them to survive in an adapted
tumour microenvironment [1].
One way cancer cells avoid the accumulation of intracellu-
lar acid is by the up-regulation of proton pumps (PP) and
transporters (PTI) responsible for the removal of hydrogen
ions from the intracellular compartments or cytosol to the
extracellular microenvironment. Several biological mecha-
nisms exist to export hydrogen ions out of the cells and to
affect the extracellular pH including the carbonic anhydrase
(CA) enzymes (and in particular CA IX) [9], the mono-
carboxylic transporters (MCT), the Vacuolar-H+−ATPase
(V-ATPase) and the Na+/H+ transporters (NHE) [1] (Fig. 1).
Of all the 16 isoforms of CA, CA IX seems to be
prevalent in cancer. Whilst in non-disease states CA IX
expression is limited to the gut epithelium (namely the
basolateral surfaces of the cryptic enterocytes), CA IX is
ectopically expressed in a variety of neoplastic tissues
and knockdown of CA IX expression (or its chemical in-
hibition) has been shown to reduce primary tumor
growth, and decrease drug resistance. CA catalyzes the
removal of a water molecule from carbonic acid group
and as a result can affect the pH of the extracellular en-
vironment [9] (Fig. 1).
Lactate is a byproduct from glucose breakdown through
glycolysis in anaerobic conditions. As a means of regener-
ating oxidized NAD+, lactate dehydrogenase catalyzes the
conversion of pyruvate to lactate in the cytosol. The
transport of the acid lactate is ensured via specific trans-
porters known as monocarboxilate transporters. Of all the
14 MCTs, expression and regulation of MCT1, MCT2,
MCT3 and MCT4 have been reported in a wide variety of
cancers. Upon transport, the proton and lactate anion are
associated as they cross the cell membrane resulting in a
net efflux of proton outside cancer cells [10] (Fig. 1).
V-ATPases are proton (H+) pumps that actively transport
H+ out of the cell using ATP [9, 11]. They are membrane
proteins expressed at the level of the plasma membrane
and intracellular membrane organelles. V-ATPases are
composed of V0, a membrane complex, and V1, a soluble
domain [12]. V0 is the integral site responsible for the
movement of H+ across the plasma membrane, whereas V1
is responsible for ATP hydrolysis [13] (Fig. 1).
Na+/H+ antiporters remove H+ in exchange for Na
+(1H+:1Na+). NHE is composed of two complexes, the C-
terminal and the N-terminal regulating the activity of the
cytoskeleton and the ion transportation, respectively [14].
Different isoforms exist, with NHE1 being ubiquitous and
NHE2 and NHE3 largely expressed in the kidney and intes-
tine [12] (Fig. 1).
The ability to efflux protons from cells and therefore
change the extracellular pH provides an advantage to
cancer cells. For instance, the weakly basic cytotoxic drugs
(e.g. doxorubicin) used in chemotherapy protocols are
neutralised by the lowered pH. In this way, drugs are
protonated when they reach the acidic barrier surrounding
the cell and are subsequently unable to pass through the
cell membrane [15]. V-ATPases have been shown to be
Fig. 1 pH regulation in cancer cells. A number of proteins and chemical reactions regulates pH in cells. The present review focuses on NHE1 and
V-ATPase. 1: CAs, 2: ATP-Synthase, 3: NHE1, 4: MCTs, 5: V-H+-ATPase, 6: Cl−/HCO3
−. pHi = Intracellular pH. pHe = Extracellular pH [28]
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associated with multidrug resistance which can be
reversed by using inhibitors of these proton pumps [5].
Other survival mechanisms that cancer cells have devel-
oped as a result of the acidic microenvironment are the up-
regulation of drug transporters at the cell membrane [16],
and alteration of the biophysical properties of the mem-
brane [17–19] which are responsible for the efflux of the
cytotoxic drugs and the onset of drug resistance. In order
to overcome these challenges, therapies use high concentra-
tions of drugs from the start of the therapy or use another
additional drug, which inevitably result in more negative
side effects for patients. Moreover, the tumour acidic envir-
onment negatively affects the immune system, leading to a
state of local anergy that prevents the immune cells
from exploiting the tumour shrinkage and the expos-
ure of tumour antigens that follows a successful
chemotherapy [20].
The acidic tumour microenvironment has also been asso-
ciated with the degree of cancer aggressiveness. It has been
reported that the lower the pH surrounding the cell, the
more likely is the chance of malignancies with higher
degree of invasiveness [16]. This can be due to the in-
creased lysosomal exocytosis of intracellular proteases
which occurs secondary to the acidic microenvironment.
These proteases can affect the extracellular matrix in the
surrounding tissue and may induce the invasion of the
surrounding tissues [16, 21]. Some studies suggest that can-
cers with low metastatic potential utilise mostly Na+/H+
exchangers, whereas highly metastatic cancers use V-
ATPases [22]. Therefore, the ability to manipulate the
acidity of the cancer cells microenvironment presents novel
therapeutic opportunities to prevent the progression and
spread of cancer [15, 23–25].
Proton pump inhibitors
In an attempt to manipulate and neutralise this acidic
microenvironment, proton pump inhibitors (PPIs) have
been used to target the V-ATPase pumps present on the
cell membrane. The treatment leads to an alkalisation
which subsequently reduces the degree of protonation of
chemotherapy drugs rendering them far more effective
at much lower doses [26].
The specific inhibitor of V-ATPase pumps Bafilomycin
has been evaluated for its antineoplastic activity [27] but
it was demonstrated to be highly toxic to normal cells
even at low doses [28]. Other studies have also looked at
the use of the diuretic Amiloride to block the transport of
protons out of the cell via the NHE transporter [16], and
several studies have demonstrated anti-tumours and anti-
metastatic activity in cancer cells and animal models [29].
PPIs used as irreversible blockers of the gastric H+/K+
ATPase pump have been also demonstrated to be effect-
ive on V-ATPases at higher concentrations [30, 31].
Because of their similarity, these inhibitors which are
routinely used as antacids, are at the most advanced
stages of clinical use compared to other H+ pump inhib-
itors [32]. This class of drug chemicals present a definite
advantage as they only become active in an acidic envir-
onment and as a result can selectively target cancer cells
in their acidic environment [33]. In addition, they are
well tolerated and safe, with severe side effects only rarely
reported [34]. They have therefore been successfully used
to suppress tumour growth in vitro and in vivo and to
overcome drug resistance [24, 33].
Proton pump inhibitors (PPIs) are the treatment of
choice for acid-related disorders. Omeprazole was the
first PPI to be approved by the FDA in 1989 to treat
heartburn and other symptoms associated with gastro-
esophageal reflux disease in humans. FDA approved five
more PPIs since then, lansoprazole, pantoprazole, rabe-
prazole, esomeprazole and dexlansoprazole. The last two
drugs are enantiomers of omeprazole and lansoprazole,
respectively (Fig. 2a) [35]. PPIs are acid-activated pro-
drugs [36]: since PPIs are weak bases (pKa1 = 3.8-4.9),
they are only accumulated in acidic tissues such as parietal
cells where the pH can go as low as 1. The concentration
of PPIs at the luminal surface of the pump is roughly
1000-fold higher than their concentration in the blood.
This selective accumulation of PPIs is largely the reason
for their high therapeutic index. Mechanistically, the
protonation of the pyridine moiety of PPIs initiates a
series of reaction leading to the formation of a sulfenic
acid and sulfenamide. The latters are highly reactive thio-
philic species which will react covalently with different
ATPase cysteines to form stable disulfides, thus inhibiting
the acid secretion (Fig. 2b) [37, 38].
Proton pump inhibitors as cancer treatment
Because cancers develop in an acidic environment and they
express high levels of proton pumps, there may be advan-
tages in using PPIs and proton transporter inhibitors (PTIs)
as a universal treatment across all forms of cancer with
relatively few associated side effects [23]. PPIs have also
been linked with an increase in cellular caspase activity and
an early accumulation of reactive oxygen species within the
cell, all of which result in an increased rate of apoptosis
[23]. This direct cytotoxic effect has been supported by
several studies showing that PPIs can induce apoptosis in
both hematopoietic and solid cancers [5]. Another import-
ant effect of PPIs is associated with the modulation of
autophagy in cancer cells [39, 40]. Chronic autophagy has
been established as a pro-survival adaptation of cells to the
acidic tumour microenvironment [41]. Importantly, PPIs
have been show to inhibit mTOR signalling, a major regu-
lator of cell growth and autophagy possibly as a conse-
quence of the acidification of the intracellular pH [32].
Beside the direct toxic effects, PPIs may have additional
cancer-modulating effects. Increasing the pH of the
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microenvironment reverses multi drug resistance. There
are a number of explanations behind this observation.
Firstly, all drugs that are weak base with a pKa around 8
are usually protonated at neutral or low pH. As a result,
they cannot cross the bilayer membrane and remain in
the acidified milieu (corresponding to the extracellular
milieu or intracellular organelles as endosomes or lyso-
somes). The efflux of protons has been demonstrated to be
involved in drug resistance and it is therefore possible to
revere drug resistance using either PPIs or PTIs [42]. Sec-
ondly, for the anticancer drugs that are not weak bases (but
weak acid or neutral) and that therefore should cross the
bilayer membrane at low pH, another mechanism involving
an increase in the membrane stiffness due to the electro-
static repulsion between negatively charged lipids forming
the inner leaflet of the membrane in direct contact with the
alkaline cytosol, can block drugs mechanically [17]. In this
case, acidifying the cytosol by blocking proton efflux can
soften the membrane and reverse the low drug uptake.
These pH/membrane dependent mechanisms are well
known to work in concert with drug transporters meaning
that it is possible to alter drug transporters activity by
blocking proton efflux [17].
A study using both human and mouse cell lines found
that pre-treatment with PPIs caused the xenograph
tumours to reduce in size when compared to using the
cytotoxic drug doxorubicin alone which resulted in the
tumour remaining static in size [15]. These results sug-
gest that cancer cells were more sensitive to doxorubicin
with PPIs pre-treatment.
Increasing the pH of the microenvironment should
also lead to a reduction in the amount of proteases being
release from cells via exocytosis, thereby reducing the
invasiveness and ability of the cancer to form metastasis.
A study found that oral supplementation of sodium
bicarbonate in xenograft mouse models of metastatic
breast and prostate cancers was able to alkalise the
acidic microenvironment of cancers resulting in a de-
crease in the number of metastases [43]. The Whitaker
Wellness Institute is currently trialling an ‘alkalinizing
therapy’ in their human patients [28, 43].
Proton pump inhibitors in human and veterinary clinical
oncology
PPIs have been met with outstanding success in both in
vitro and in vivo pre-clinical studies [23]. Clinical trials
have been performed and others are currently underway
in human medicine. For instance, studies looked at the
use of esomeprazole as chemosensitiser in neo-adjuvant
chemotherapy for the treatment of osteosarcoma [15] and
Fig. 2 a Chemical structure of FDA-approved PPIs. b Mechanism of action of PPIs
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as combination treatment with cisplatin and docetaxel in
metastatic breast cancer (ClinicalTrials.gov Identifier:
NCT01069081). It has been shown that pre-treatment of
cancer patients with PPIs prior to the chemotherapy is
effective on a number of different tumour types and there
is a direct correlation between the ability of the PPIs to
change the extracellular pH and the number of H+ trans-
porters in the cell membrane [23].
There is currently limited information as to whether can-
cers in animals share the same pathological characteristics
compared to the human counterpart in terms of tumour
microenvironment. There have been a number of studies
performed in transgenic mice and cell lines, however very
little is known about the pathogenesis of spontaneously
occurring tumours in companion animals. There is even
less information available in the other species such as
horses or exotic animals. Table 1 outlines the species varia-
tions in the prevalence of different forms of cancer by site
affected. However, many spontaneous cancers in compan-
ion animals share the same pathology, molecular character-
istics and clinical progression to the human counterparts
and therefore it is reasonable to speculate they should
respond to PPIs.
Recently, a clinical trial performed in both dogs and cats
by Spugnini et al. [44] supported this hypothesis. The phase
I/II study conducted in 34 companion animals has shown
that treatment with the PPI lansoprazole combined with
chemotherapy resulted in a positive outcome for the major-
ity of the animals, either showing partial or complete re-
sponse [44].
Therefore, the results from this clinical trial are very posi-
tive as the treatment with PPIs resulted in the down staging
of tumours with the vast majority of patients having few
significant clinical side effects to the high doses of PPIs
given, mostly limited to vomiting and diarrhoea secondary
to gastric hypochloridia. A case worthy of note within the
study is that of a cat with an aggressive lymphoma which
had spread to the pancreas and was unresponsive to
chemotherapy. The cat went into complete remission after
receiving the alkalizing treatment and remained disease free
in excess of one year.
More recently, it has been shown that alkalization with a
water alkalizer and high dose of lansoprazole increased the
efficacy of metronomic chemotherapy in a cohort of dogs
and cats with advanced cancer disease [44, 45]. Although
this study had some limitations including low number of
patients and inability to proper measure the variation of pH
in the alkaline cohort, it shows that the manipulation of
tumor microenvironment can be exploited in metronomic
chemotherapy as well.
The direct cytotoxic effect of the PPIs may present the
opportunity for an alternative treatment if owner’s financial
constraints cannot allow for expensive chemotherapy treat-
ments or in case of tumour chemoresistance.
This is supported by evidence collected during in vitro
preliminary studies performed by the authors which
showed cellular death was increased in a dose dependent
manner using the PPI omeprazole and the NHE blocker
amiloride in canine osteosarcoma cells (Fig. 3a). The study
performed in chemoresistant sarcospheres derived from
canine osteosarcoma cells shows a dose dependent toxic
response to the PPI and NHE blocker. In addition , the re-
sults show increased cell death when the sarcospheres were
pre-treated with PPI/NHE blocker compared to using
doxorubicin or cisplatin alone (Fig. 3b).
An added advantage of using PPIs in veterinary medicine
is its ease of handling. There are no strict health and safety
guidelines set in place as with cytotoxic drugs. Currently,
caution must be exerted when preparing and handling
chemotherapy drugs, and care must be taken by owners
and veterinary staff not to come into contact with the ani-
mals bodily fluids for several days after chemotherapy
treatment. No specialist facilities are required for PPIs and
they could be easily available to all clinicians and owners.
Two case reports interfering with the Warburg effect in
cancer
Some of the authors of this manuscript are currently treating
several veterinary patients with a combination of alkalizing
therapy and chemotherapy (classic systemic, loco-regional or
metronomic). The outcomes of two paradigmatic cases are
reported below.
Case report 1
A 15 year old male mixed breed dog was referred for
oncology consult due to persistent coughing that lasted in
excess of one month, unresponsive to symptomatic ther-
apy. The dog was quiet, alert and responsive at physical
exam, cardiac function upon auscultation was within
normal limits, in the right thoracic side respiratory sounds
were muffled and there was a 5 cm area were the sounds
could not be appreciated at all. Cough was easily induced
upon tracheal stimulation. Haematological analysis and
biochemical profile showed a mild anaemia (5.2 x 106/μL
Table 1 List of most prevalent cancer types in the individual species
Prevalence Human Dog Cat Horse Rabbit Reptile/chelonian Ferrets
1 Breast/Prostate Breast Lymphoid Skin Uterine adenocarcinoma Soft tissue sarcoma Insulinoma
2 Lung Skin Skin Lymphoma Lymphosarcoma Lymphoma Lymphoma
3 Colon/Rectum Connective tissue Breast Unknown Embryonal nephroma Fibrosarcoma Adrenal
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RBC with a lower limit of 5.5). Chest radiographs
evidenced a mass in the left lung. At this point a CT scan
study was deemed necessary to perform a biopsy under
guidance (Fig. 4a). The report came back with a diagnosis
of bronchogenic carcinoma. The treatment options were
discussed with the owner and included lobectomy com-
bined with systemic chemotherapy, systemic chemotherapy
alone or metronomic chemotherapy with alkalinisation of
the patients. The owner, due to emotional and financial
issues chose the third option. The patient was treated with
a combination of daily cyclophosphamide, piroxicam and
lansoprazole as previously described [45] combined with a
water alkalizer. The therapy was well tolerated and the
cough subsided, while the patient showed an increased
activity level as well as improved quality of life. Side effects
were confined to 3 episodes of grade 2 gastrointestinal
toxicoses [46] and a mild worsening of the anemia after
8 months of therapy (RBC 4.8 × 106/μL). After 14 months
a
b
Fig. 3 Dose response toxicity curve of canine osteosarcoma D17 sarcospheres treated with omeprazole and amiloride, as assessed by flow cytometry
(a). Effect of pre-treating sarcospheres with omeprazole and amiloride prior to treatment with doxorubicin and cisplatin versus chemotherapeutic drug
alone (b)
Fig. 4 Metronomic chemotherapy with patient alkalization in a 15 year old mixed breed with lung carcinoma. a Tumor appearance at presentation
(CT scan imaging). b Tumor appearance after 14 months of therapy (thoracic radiograph imaging)
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the patient is still in a condition of stable disease and is
monitored with chest radiographs every two months
(Fig. 4b).
Case report 2
A 10 year old Arabian mare was referred for multiple
muco-cutaneous melanoma and for failure at conceiving.
At presentation the horse was bright alert and responsive
(Fig. 5a) and presented several melanomas ranging in size
from 2 to 8 cm. Ultrasonographic examination was per-
formed showing multiple lymph-nodal metastasis within
the abdomen, some of them compressing the uterus and
adnexa. Systemic chemotherapy treatment with platinum
compounds was deemed unrealistic due to the widespread
disease and related expenses with this therapy. At this
point, intralesional chemotherapy with CDDP was offered
as a palliation. The first course did not result in any meas-
urable response and patient alkalization was then sug-
gested. Considering the amount of PPI or H2 blockers
needed to achieve this goal, a different approach was pro-
posed: intralesional administration of bicarbonate com-
bined with diet supplementation with the same substance
since it is palatable to the horses. In this patient were
performed 4 sessions of intralesional 8.4 % (w/v) bicarbon-
ate solution followed by intralesional CDDP 0,5 % (w/v)
solution under ultrasonographic guidance (Fig. 5b and c).
This therapy yielded a 50 % lymph nodes tumour reduc-
tion after 3 sessions. The treatment was discontinued after
the 4th session due to financial concerns. The horse has
been kept on bicarbonate supplementation as maintenance
and is actually experiencing a robust partial remission last-
ing in excess of two years. Throughout this period the
mare has been showing a good quality of life. Side
effects secondary to the therapy have not been re-
ported. Alkalization obtained through diet supple-
mentation or through the administration of pump
inhibitors can be a valuable strategy to improve the
efficacy of standard as well as non-conventional
chemotherapy in veterinary oncology.
Conclusions
The importance of Warburg effect in cancer including the
role of proton pumps is now underlined almost every day
in the cancer literature [47–54]. PPIs are amongst the
most commonly prescribed drugs in human medicine and
have gone through the process of rigorous safety testing
and monitoring. Very few clinical side effects have been
reported at higher doses. In case controlled studies, long
term treatment with PPIs was associated with increased
risk of bone fracture. Some reports have suggested
increased risk of gastric or colon cancer, but these studies
are still inconclusive [5]. Therefore it is reasonable to
justify the continued investigation into the use of this class
of drugs for the treatment of cancer in humans and
companion animals. They may provide an alternative or
additional source of therapy which could result in more
effective and lower cost treatments. They could potentially
form part of a universal treatment which may have direct
benefits in treating a number of different cancer types
while overcoming problems associated with chemother-
apy, such as drug resistance and patient discomfort. None
of the PPIs is currently licenced for use in veterinary medi-
cine and more research is needed to support their value as
new treatment for veterinary cancer patients.
Fig. 5 Loco-regional chemotherapy with patient alkalization in a 10 year old Arab mare. a Patient at presentation. b Ultrasound-guided intralesional
chemotherapy with alkalization. c Tumor appearance after the 4th session
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